𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Experience with oral interferon-alpha in patients with essential thrombocythemia and polycythemia vera

✍ Scribed by Alfonso Quintás-Cardama; Srdan Verstovsek

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
119 KB
Volume
82
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

α-2a interferon therapy and antibody for
α-2a interferon therapy and antibody formation in patients with essential thrombocythemia and polycythemia vera with thrombocytosis
✍ E. Törnebohm-Roche; M. Merup; D. Lockner; Dr. C. Paul 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 479 KB 👁 1 views

In ten patients with essential thrombocythemia and polycythemia Vera with thrombocytosis we have investigated the therapeutic effect of recombinant a-2a interferon (Roceron-A@) given subcutaneously in a maintenance dosage of 3 million units three times weekly. The aim was to normalize the platelet

Genetic lesions associated with blastic
Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia
✍ Gianluca Gaidano; Cristina Pastore; Valeria Santini; Josep Nomdedeu; Barbara Gam 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 2 views

Polycythemia vera (PV) and essential thrombocythemia (ET) are chronic myeloproliferative disorders that may progress to acute leukemia in a subset of patients. This study aimed at investigating the genetic lesions associated with the blastic transformation of PV and ET. A panel of PV and ET cases at

Leukemogenic risk of hydroxyurea therapy
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
✍ Nand, Sucha; Stock, Wendy; Godwin, John; Fisher, Susan Gross 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 417 KB 👁 2 views

In polycythemia Vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%. This risk has been estimated to be 1-5.9% with hydroxyurea (HU) therapy. When compared with historical controls, the risk with use of HU does not a

LONG-TERM CONTROL OF POLYCYTHEMIA RUBRA
LONG-TERM CONTROL OF POLYCYTHEMIA RUBRA VERA WITH RECOMBINANT ALPHA INTERFERON
✍ M. J. CLEMONS; Y. F. WILLIAMS; J. M. GOLDMAN; A. J. BARRETT 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB 👁 1 views

The natural history of PRV is characterized by a prolonged period of myeloproliferation chiefly affecting the red cell series. It can be controlled by venesection and cytotoxic agents. In this case report the patient declined further 'standard' chemotherapy to control his disease and the use of rela